The Ford Effect

The Ford Effect

This morning Dexcom released a new report of the state of Type 2 diabetes. The report was revealing in many aspects not all of which were anticipated by Dexcom who understandably is using it to sell more sensors to patients with Type 2 diabetes. Now with an OTC indication Dexcom has an opportunity to do something their rival Abbott should have done years ago and could have dome years ago.

As it stands today insulin using patients drive the CGM market. This is understandable as these patients use the data to make insulin dosing decisions. However, uptake with patients who . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.